- Home
- AMGN vs AMD Comparison
AMGN vs AMD Comparison
Compare AMGN & AMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- AMD
- Stock Information
- Founded
- AMGN 1980
- AMD 1969
- Country
- AMGN United States
- AMD United States
- Employees
- AMGN N/A
- AMD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- AMD Semiconductors
- Sector
- AMGN Health Care
- AMD Technology
- Exchange
- AMGN Nasdaq
- AMD Nasdaq
- Market Cap
- AMGN 156.2B
- AMD 143.4B
- IPO Year
- AMGN N/A
- AMD 1972
- Fundamental
- Price
- AMGN $265.86
- AMD $102.84
- Analyst Decision
- AMGN Buy
- AMD Buy
- Analyst Count
- AMGN 19
- AMD 35
- Target Price
- AMGN $324.37
- AMD $136.19
- AVG Volume (30 Days)
- AMGN 2.7M
- AMD 39.8M
- Earning Date
- AMGN 05-01-2025
- AMD 05-06-2025
- Dividend Yield
- AMGN 3.58%
- AMD N/A
- EPS Growth
- AMGN 56.16
- AMD 99.41
- EPS
- AMGN 10.94
- AMD 1.37
- Revenue
- AMGN $34,126,000,000.00
- AMD $27,750,000,000.00
- Revenue This Year
- AMGN $7.19
- AMD $22.31
- Revenue Next Year
- AMGN $2.37
- AMD $20.12
- P/E Ratio
- AMGN $24.29
- AMD $75.07
- Revenue Growth
- AMGN 15.56
- AMD 21.71
- 52 Week Low
- AMGN $253.30
- AMD $76.48
- 52 Week High
- AMGN $346.85
- AMD $187.28
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- AMD 58.71
- Support Level
- AMGN $268.81
- AMD $96.88
- Resistance Level
- AMGN $291.61
- AMD $105.44
- Average True Range (ATR)
- AMGN 7.54
- AMD 3.46
- MACD
- AMGN -0.76
- AMD 1.41
- Stochastic Oscillator
- AMGN 0.76
- AMD 87.17
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About AMD Advanced Micro Devices Inc.
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.